RYSTIGGO is manufactured by UCB, a global biopharmaceutical company.
Detailed Information About RYSTIGGO's Manufacturer
According to the regulated information released on June 27, 2023, UCB (Euronext Brussels: UCB), a global biopharmaceutical company, announced that RYSTIGGO® (rozanolixizumab-noli) had been approved by the U.S. Food and Drug Administration (FDA).
This announcement clearly establishes UCB as the maker of RYSTIGGO. This drug is a treatment for generalized myasthenia.
Key Takeaways:
- Company: UCB is a global biopharmaceutical company.
- Product: RYSTIGGO® (rozanolixizumab-noli).
- Approval: The U.S. FDA approved RYSTIGGO.
- Treatment: RYSTIGGO is used to treat generalized myasthenia.
- Announcement Date: The official announcement was made on June 27, 2023.
The reference specifically names UCB as the manufacturer behind RYSTIGGO. For more information, one can refer to the official press release by UCB.
